Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 3Uterine Cervical Neoplasms 2Sarcoma, Ewing 2Vaginal Neoplasms 1Stomach Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oropharyngeal Neoplasms 1Locally Advanced Cervical Adenocarcinoma 1Ganglioneuroblastoma 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 15Cisplatin 13durvalumab 10pembrolizumab 9Oxaliplatin 8Magnetic Resonance Spectroscopy 8Specimen Handling 6Leucovorin 6Biopsy 6Fluorouracil 5Paclitaxel 4Folfox protocol 4Taxes 3Radiation 3Nivolumab 3Irinotecan 3Immunoglobulin G 3Disulfides 3tislelizumab 2pemigatinib 2olaparib 2futibatinib 2fludarabine 2dehydroftorafur 2Platinum 2Liver Transplantation 2Fluorodeoxyglucose F18 2Floxuridine 2Dexamethasone 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Congresses as Topic × 90 days × Clear all
NCT03942328 2026-04-20

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Mayo Clinic

Phase 1/2 Recruiting
85 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡